Ned Sharpless currently leads the cancer center at the University of North Carolina, Chapel Hill.

A new approach to immunotherapy finds that the immune-cell clonotypes that come to the rescue start out at very low frequencies.

In the middle of the 20th century, the National Cancer Institute began testing plant extracts for chemotherapeutic potential—helping to discover some drugs still in use today.

Researchers unravel the sophisticated ways cancers evade treatments, including immunotherapies, designed to destroy them.

Neoantigens may serve as valuable targets for new immunotherapies.

Cancers appear to be able to evolve resistance to many of the therapies doctors have tried.

Vaccine-induced macrophages open a new realm of study into remodeling the immune system to reduce the risk of infections during cancer treatment.

New approaches to treating cancer have shown great promise, but they also come with serious risks that give us cause for concern.

The pharma giant is purchasing the San Francisco–based cancer drugmaker to boost its oncology portfolio.

Alfred Knudson, who formulated the “two-hit” theory on the origins of cancer, has passed away at age 93.